 Patent Application Title |
Patent App Num. |
Date |
 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof | 20130149378 | 20130613 |
 An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50... |
| Production of dha and other lc-pufas in plants | 20130150599 | 20130613 |
 The invention provides recombinant host organisms (e.g., plants) genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins (e.g., PPTase and/or ACoAS) that allow for and/or improve the production of PUFAs in the host organism. The present invention also relates to methods of making and using such organisms (e.g., to obtain PUFAs) as well as products obtained from such organisms (e.g., oil and/or seed).
... |
| Production of high levels of dha in microalgae using modified amounts of chloride and potassium | 20130150604 | 20130613 |
 Methods for production of highly unsaturated fatty acids by marine microorganisms, including the heterotrophic marine dinoflagellate Crypthecodinium, using low levels of chloride ion are disclosed. Specifically, methods of increasing production of highly unsaturated fatty acids by marine microorganisms while growing in low chloride media by manipulating sodium ion and potassium ion levels. The invention also relates to methods of production of highly unsaturated fatty acids by marine organisms at low pH levels, and includes methods for generation of low pH tolerant strains.
... |
| Poultry meat and eggs comprising beneficial fatty acids | 20130095205 | 20130418 |
 The present disclosure provides for improved poultry products and methods of producing such poultry products by incorporating healthy lipids containing stearidonic acid into animal feed products. Furthermore, the present disclosure provides methods for producing said products. In one embodiment of the disclosure, a poultry animal may be fed feed comprising a transgenic plant product. In other embodiments of the disclosure, poultry white meat and dark meat products comprising SDA, EPA, DPA, and DHA are disclosed. In further embodiments of the disclosure, poultry eggs comprising SDA, EPA, DHA, and DPA are disclosed.
... |
| Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels | 20130079310 | 20130328 |
 A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
... |
Subscribe to updates on this page: DHA RSS  |
| Lipid compositions with high dha content | 20130059768 | 20130307 |
| The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
... |
| Omega 3 fatty acidfor use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levels | 20130040913 | 20130214 |
| The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for... |
| Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events | 20130040927 | 20130214 |
| A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
... |
| Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics | 20130034535 | 20130207 |
| Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.
... |
| Liquid enteral nutritional composition suitable for tube feeding, minimizing lower and upper tract digestive conditions | 20130023468 | 20130124 |
| The invention is directed to liquid enteral nutritional compositions comprising a protein fraction comprising more than 25 weight % and up to 80 weight % of a vegetable protein comprising at least a source of pea protein, and a fat fraction comprising (a) 8 to 15 weight % of linoleic acid; (b) 3.0 to 6.0 weight % of a combination of alpha-linolenic acid, docosahexaenoic acid and eicosapentaenoic acid, wherein the amount of ALA is >2.5 weight % and the combined amount of DHA and EPA is ≦2.5 weight %; (c) 10 to 20 weight % of at least one medium-chain fatty acid; and (d) 35 to 79 weight % of at least one mono-unsaturated fatty acid. The compositions provide for a healthy and balanced diet, which... |
| Solvent-free process for obtaining phospholipids and neutral enriched krill oils | 20130012449 | 20130110 |
| The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater.
... |
| Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome | 20130005692 | 20130103 |
| A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.
... |
| Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death | 20120302639 | 20121129 |
| A formulation for treating omega-3 fatty acid deficiency is disclosed containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. EPA+DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of... |
Subscribe to updates on this page: DHA RSS |
| Nutritional composition for supporting brain development and function of toddlers | 20120276057 | 20121101 |
| The present invention relates to a nutritional composition, in particular directed to toddlers and/or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises sphingomyelin, sialic acid, choline, essential fatty acids and taurine.
... |
| Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases | 20120277317 | 20121101 |
| A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided.
... |
| Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma | 20120264713 | 20121018 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the... |
| Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | 20120258181 | 20121011 |
| The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.
... |
| Aquaculture feed compositions | 20120213905 | 20120823 |
| Aquaculture feed compositions having a ratio of concentration of omega-3 polyunsaturated fatty acids of eicosapentaenoic acid [“EPA”; cis-5,8,11,14,17-eicosapentaenoic acid; 20:5] to concentration of docosahexaenoic acid [“DHA”; cis-4,7,10,13,16,19-docosahexaenoic acid; 22:6] greater than 2:1 based on the individual concentrations of EPA and DHA in the aquaculture feed composition, and having a biomass source of carotenoid(s), are disclosed. Furthermore, such aquaculture feed compositions may have a concentration of the sum of EPA and DHA that is at least about 0.8%, measured as a weight percent of the aquaculture feed composition.
... |
| Aquaculture meat products | 20120207912 | 20120816 |
| Aquaculture meat products having a ratio of omega-3 polyunsaturated fatty acids of eicosapentaenoic acid [“EPA”; cis-5, 8, 11, 14, 17-eicosapentaenoic acid; 20:5], to docosahexaenoic acid [“DHA”; cis-4, 7, 10, 13, 16, 19-docosahexaenoic acid; 22:6], equal to or greater than 1.4:1 based on the individual concentrations of each as a percent of the total fatty acids in the aquaculture meat product are disclosed. Furthermore, such aquaculture meat products may have a concentration of the sum of EPA and DHA that is at least about 0.5%, measured as a weight percent of the aquaculture meat product.
... |
| Highly purified ethyl epa and other epa derivatives | 20120195963 | 20120802 |
| A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
... |
| Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k | 20120195987 | 20120802 |
| Medicaments and therapeutic compositions comprise a composition (1) comprising (A) EPA, pharmaceutically acceptable derivatives of EPA or mixtures thereof, and, optionally, (B) DHA, pharmaceutically acceptable derivatives of DHA or mixtures thereof, wherein the weight ratio of A:B is about 7.5:1 or more, and a composition (2) comprising monacolin K, a source of monacolin K or mixtures thereof. One source of component (1) is fish oil. One source of monacolin K is Red Yeast Rice extract. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.
... |
| Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof | 20120196934 | 20120802 |
| Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.
... |
| Removal of monoglycerides from fatty acid concentrates | 20120184760 | 20120719 |
| Unsaturated fatty acids, in particular highly unsaturated acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are typically provided in the form of ethyl esters. A major challenge in the concentration of EPA and particularly DHA by molecular distillation, is the accumulation of monoglycerides in the product. The present invention offers a solution to completely remove the monoglycerides from the ethyl ester products.
... |
| Nutritional composition for supporting brain development and function of toddlers | 20120171177 | 20120705 |
| The present invention relates to a nutritional composition, in particular directed to toddlers and/or a weaning child, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid). The nutritional composition improves cognitive performance, in particular learning and memory of the child. Preferably, the composition comprises iron, zinc, vitamin D and/or sialic acid. Preferably, the composition comprises a source of phospholipids rich in DHA.
... |
| Nutritional composition for supporting brain development and function of children | 20120171178 | 20120705 |
| The present invention relates to a nutritional composition, in particular directed to children of 3-6 years, said nutritional composition comprising a protein source, a source of available carbohydrates, a lipid source, at least one probiotic microorganism, and prebiotics, wherein said lipid source comprises DHA (docosahexaenoic acid) and/or ARA (arachidonic acid). The nutritional composition improves cognitive performance, in particular memory, learning comprehension, alertness, attention, concentration, processing speed, conceptual thinking, abstract thinking, verbal abilities, language comprehension, psychomotor skills, curiosity, and confident interaction with the environment. Preferably, the composition comprises one, a combination of several or all selected of the group of DHA, ARA, LA, ALA, choline, iron, iodine and folic acid.
... |
| Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k | 20120171311 | 20120705 |
| Medicaments and therapeutic compositions comprise (1) a mixture comprising (A) EPA, pharmaceutically acceptable derivatives of EPA or mixtures thereof, and, optionally, (B) DHA, pharmaceutically acceptable derivatives of DHA or mixtures thereof, wherein the weight ratio of A:B is about 7.5:1 or more, and (2) monacolin K, a source of monacolin K or mixtures thereof. One source of component (1) is fish oil. One source of monacolin K is Red Yeast Rice extract. The compositions are useful for lowering cholesterol and/or triglyceride levels in a subject.
... |
| Omega 3 fatty acid formulations | 20120172431 | 20120705 |
| The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.
... |
| Pharmaceutical composition including a dha ester to be administered parenterally | 20120141563 | 20120607 |
| The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.
... |
| Skin compositions containing low levels of colorants | 20120128602 | 20120524 |
| A composition for providing enhanced skin appearance, particularly in terms of providing the appearance of reduced dryness and flakiness for an extended period of time, is disclosed. The compositions include low levels of skin coloring agents, including self-tanning compounds, such as DHA and/or erythrulose, in a topical cosmetic base. The levels of self-tanning compounds utilized are lower than those typically found in self-tanning compositions. A method for enhancing skin appearance utilizing those compositions is also disclosed.
... |
| Purifying crude pufa oils | 20120121772 | 20120517 |
| A process for preparing an oil mixture of an T6 PUFA (such as ARA) with T3 PUFA (such as DHA and/or EPA) is described which can he included into edible formulations such as foodstuffs, and in particular infant formulas. A crude T6 PUFA (e.g. ARA)-containing oil is admixed with a crude T3 PUFA (e.g. DHA or EPA)-containing oil to produce a crude oil mixture (or blend). This mixture is then purified before addition to a foodstuff Alternatively, a crude T6 PUFA-containing oil is treated, and a crude T3 PUFA-containing oil is also treated, and the two purified oils are then blended prior to deodorising and then added to a foodstuff. The purifying includes acid and/or alkali treatment, bleaching, deodorization, filtering, polishing or cooling. The purifying removes... |
| Methods of treating neurological diseases using docosahexaenoic acid and arachidonic acid compositions | 20110015160 | 20110120 |
| A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.
... |
| Method for the treatment of psychic disorders | 20110003796 | 20110106 |
| Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (ω3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3 fatty acid may be administered orally, in amounts that may be variable, for example in amounts between 0.15 and 1.00 g/kg/day. The antidepressant may be any antidepressant, preferably the antidepressant is fluoxetine or mirtazapine in sub-optimal doses.
... |
| Use of omega-3-fatty acid(s) | 20100331415 | 20101230 |
| The invention relates to the use of omega-3-fatty acid(s) in means for pain relief. The means preferably comprise highly unsaturated omega-3-fatty acid(s) that contain, above all, EPA and/or DHA. Preferably, the omega-3-fatty acid is administered in a high dose of more than 2 g, in particular more than 3 to 4 g, for pain relief.
... |
| Supporting activities of daily living | 20100331275 | 20101230 |
| The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.
... |
| Food composition for prodromal dementia patients | 20100323982 | 20101223 |
| A composition comprising (a) one or more ω-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per litre cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF.
... |
| Portable light source | 20100309651 | 20101209 |
| A portable light source for connection to a hardhat. The portable light source has a battery housing with an LED light mounted in a swivel portion that is connected to the battery housing. The housing also has a mounting post that engages an aperture on the side of the hardhat for holding the portable light source in place.
... |
| Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells | 20100303887 | 20101202 |
| The combination of pigment epithelium-derived factor (PEDF) and docosahexaenoic acid (DHA) has been discovered to act synergistically to enhance cell survival and decrease apoptosis in retinal pigment epithelial (RPE) cells. PEDF and DHA synergistically protected RPE cells by confronted with oxidative stress by blocking apoptotic cell death and increasing the synthesis of the important mediator neuroprotectin D 1. Administering a composition comprising PEDF and DHA will halt or slow down the initiation and progression of macular degeneration, retinitis pigmentosa and retinal degeneration. In addition, the topical application of the combination of PEDF and DHA was found to promote cornea nerve regeneration after refractive surgery, and thus this combination could be used to prevent the complications of refractive surgery and certain diseases, e.g., neurotrophic keratitis due to... |
| Fat containing composition | 20100298274 | 20101125 |
| A composition comprises a fat phase wherein the fat phase comprises: more than 10 wt. % DHA and/or EPA or derivatives thereof; or more than 5 wt. % GLA or a derivative thereof; or more than 10 wt. % of GLA, EPA and/or DHA in total or derivatives thereof; and secoisolariciresinol (SECO) or a derivative thereof, with the proviso that when the composition comprises GLA, the composition is substantially free of isoflavones. The composition and mixtures or blends comprising the composition may be used for the treatment of PMS and prostate conditions.
... |
| Metal and plastic oldham coupler with added retraction spline and plastic over molded features | 20100292014 | 20101118 |
| An Oldham coupler assembly capable of transferring rotary power between two shafts in a developer unit of an image forming apparatus that includes an input plate and an output plate made of metal and a star plate made in plastic mechanically coupled and positioned in between the input plate and the output plate. A spline component made of metal is rigidly and integrally attached to the input plate, the spline component including a tubular spline portion that includes a plurality of wear strips made of plastic, the output plate having a plastic material coated along a portion of an outside diameter of the output plate. The input and output plates further includes a plurality of openings to receive a plurality of wheels and pins. This structure... |
| Inflammatory disease treatment | 20100291053 | 20101118 |
| We describe a composition comprising a source of long chain polyunsaturated fatty acid, for example, docosahexaenoic acid (DHA), and a carotenoid, for example, astaxanthin and other nutrients for prophylactic and/or therapeutic use in the healing of trauma- and stress-induced inflammatory conditions.
... |
| Nutritional compositions for reducing oxidative damage | 20100291050 | 20101118 |
| A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schizandra, and suma root; superfoods comprising acerola, camu-camu, pomegranate, bilberry, blueberry, Goji berries, Acai, maitake, citrus bioflavonoids, rose hips, and Gingko biloba; probiotics comprising bifidobacterium longum, lactobacillus acidophilus, lactobacillus acidophilus DDS-1, lactobacillus bulgaricus, lactobacillus casei, and streptococcus thermophilus; and enzymes comprising amylase, papain, cellulose, lactase, lipase, protease, and bromelain. The nutritional compositions may also be provided as a meal replacement and further comprise one or more plant products, algae, vitamins, minerals, protein and MSM.
... |
| Neurofurans-indices of oxidant stress | 20100285500 | 20101111 |
| The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules.
... |
| Oil producing microbes adn method of modification thereof | 20100285105 | 20101111 |
| Disclosed are compositions and methods related to a eukaryote of the order Thraustochytriales and family Thraustochytriaceae which when cultured produce quantities of unsaturated fatty acids, such as omega 3 (n-3) and/or omega 6 (n-6) oils, such as DHA, EPA and DPA, capable of being purified and used as all such compositions are used and more, because of their means of production.
... |
| Trainline support bracket | 20100282919 | 20101111 |
| A trainline support bracket for connection to a railcar having a yoke and a coupler attached to the railcar and a coupler-uncoupling mechanism housing attached to the coupler having first and second side walls with first and second contoured recess members thereon, and having upper and lower compartments for attaching the trainline support bracket thereto. The trainline support bracket includes a main body connector having an upper connector section and a lower connector section. The upper connector section of the main body connector is for connecting to the coupler-uncoupling mechanism housing of the coupler. The trainline support bracket also includes a lower connecting bracket having a first end and a second end. The lower connector section of the main body connector is for detachably connecting to... |
| Use of artemisinin and its derivatives in cancer therapy | 20100279976 | 20101104 |
| A method for treating cancer in a mammal includes administering to the mammal in need thereof a therapeutically effective amount of artemisinin (ART) or its derivative, such as dihydroartemisinin (DHA), artemether (ARM), or artesunate (ARS) alone or in combination with a chemotherapeutic agent, such as gemcitabine and carboplatin. A method for inhibiting tumor cell proliferation includes contacting a tumor cell with ART or its derivative, such as DHA, ARM, and ARS, in an amount effective to inhibit tumor cell proliferation or in combination with a chemotherapeutic agent, such as gemcitabine and carboplatin.
... |
| Stability additives for dry dha dosage forms | 20100272792 | 20101028 |
| The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration.
... |
| Methods and compositions for promoting the neurological development of an infant | 20100267830 | 20101021 |
| The present invention relates to methods for promoting the neurological development of an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.
... |
| dha derivatives and their use as medicaments | 20100267828 | 20101021 |
| and their use as medicaments for the treatment of various diseases and conditions, for example, reduction of elevated triglyceride levels, i.e., hypertriglyceridemia, reduction of non-HDL cholesterol, reduction of glucose and HbA1c, and improvement of insulin resistance. The present disclosure also relates to a pharmaceutical composition comprising compounds of formula (I), as well as to processes for preparing compounds according to formula (I).
... |
| Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof | 20100266564 | 20101021 |
| The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising the nucleic acid molecules, polypeptides encoded by the nucleic acid molecules, compositions comprising the nucleic acid molecules or polypeptides, and methods of making and uses thereof.
... |
| Extraction and winterization of lipids from oilseed and microbial sources | 20100261919 | 20101014 |
| A process for purifying a lipid composition having predominantly neutral lipid components having at least one long chain polyunsaturated fatty acid is disclosed. The process employs contacting the lipid composition with a polar solvent, such as acetone, wherein the solvent is selected such that contaminants are less soluble in the solvent than is the long chain polyunsaturated fatty acid. The process is typically conducted at cooler temperatures, including about 0° C. Upon precipitation of the contaminants from the lipid composition, a separation is conducted to remove the precipitated material from the lipid composition. The long chain polyunsaturated fatty acids can include ARA, DPA, EPA, and/or DHA. The process of the present invention effectively winterizes lipid compositions, thereby reducing the tendency of such compositions to become hazy.
... |
| Unit dosage for brain health | 20100261669 | 20101014 |
| The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders.
... |
| Liquid egg product | 20100260911 | 20101014 |
| A novel liquid egg composition is provided in which omega-3 fatty acids, preferably including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), particularly in the form of fish oil, is added to and emulsified in liquid egg.
... |
| Kits and methods for nutrition supplementation | 20100260836 | 20101014 |
| The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.
... |
| Methods and apparatus for separating home agent functionality | 20100254401 | 20101007 |
| MIP Home Agent (HA) architectures are described that decompose, e.g., split, packet forwarding control functionality from actual data packet forwarding operations performed by a conventional MIP HA. This places MIP routing control in a node which is distinct from the tunnel end-points which perform packet forwarding operations to direct packets including a mobile's Home Address. Tunneling establishment and control functionality is implemented by what is referred to herein as decomposed HA (DHA) while data packet forwarding and redirection is performed, under the control of the DHA, by a tunneling agent (TA) node. The tunneling agent node serves as the data packet redirection node for a mobile as it moves from one location to another and may be located outside of a firewall used to protect the... |
| Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions | 20100239660 | 20100923 |
| The present invention relates to a product and method for delivering of DHA and EPA in need of omega-3 treatment. It involves administering a liquid formulation such as an oil containing DHA and EPA in a ratio that closely resembles the ratio of DHA and EPA in the human body. The result is a composition that performs as good or better than fish based compositions containing omega-3 fatty acids and can be dosed into smaller volumes when administering mega doses of 1000-2000 mg of DHA to a selected patient.
... |
| Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae | 20100236137 | 20100923 |
| Provided herein are systems and methods for producing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and/or derivatives and/or mixtures thereof by growing algae that produce the oils containing EPA and/or DHA and/or derivatives and/or mixtures thereof, harvesting the algae with fish in one or more enclosed systems, and then processing fish to separate and purify the EPA and/or DHA. The multi-trophic systems provided herein comprise at least one enclosure that contains the algae and the fishes, and means for controllably feeding the algae to the fishes. Also provided herein are the lipid compositions extracted from the fishes.
... |
| Poultry meat and eggs comprising beneficial fatty acids | 20100233313 | 20100916 |
| The present disclosure provides for improved poultry products and methods of producing such poultry products by incorporating healthy lipids containing stearidonic acid into animal feed products. Furthermore, the present disclosure provides methods for producing said products. In one embodiment of the disclosure, a poultry animal may be fed feed comprising a transgenic plant product. In other embodiments of the disclosure, poultry white meat and dark meat products comprising SDA, EPA, DPA, and DHA are disclosed. In further embodiments of the disclosure, poultry eggs comprising SDA, EPA, DHA, and DPA are disclosed.
... |
| Methods of using plants containing the gdha gene | 20100223693 | 20100902 |
| Disclosed are new effects of increased gdhA gene expression on plants that are susceptible to Aspergillus and Fusarium virguliforme infection. Plants transformed with the gdhA gene are resistant to aflatoxin accumulation following Aspergillus infection, and to root rot following F. virguliforme infection. The resistance to aflatoxin accumulation and root rot in gdhA+ plants is coincident with drought tolerance and resistance of the plants to certain herbicides. Methods for controlling aflatoxin contamination and root rot in crop plants, and for screening plants putatively transformed with gdhA, are described.
... |
| Scroll type compressor | 20100215536 | 20100826 |
| In a scroll type compressor including a fixed scroll having a mirror plate and a lap provided to the mirror plate, a movable scroll having a mirror plate and a lap provided to the mirror plate and engaged with the fixed scroll, and an Oldham's ring disposed on the back side of the movable scroll for constraining rotation of the movable scroll on the axis thereof, the Oldham's ring has a pair of fixing locking pawls extending from the back side of the movable scroll and fitted to the fixed scroll, each of the fixing locking pawls is provided with a reinforcing portion at the base portion thereof, and the mirror plate of the movable scroll is cut out in a concave shape at the edge... |
| Vitamin/mineral composition with dha | 20100203160 | 20100812 |
| Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.
... |
| Long chain polyunsaturated fatty acids and methods of making and using the same | 20090318394 | 20091224 |
| Disclosed are compositions containing DHA and DPAn-6 and methods of administering and using the same to treat or prevent at least one symptom of inflammation or neurodegeneration or disease states associated with inflammation or neurodegeneration. Also discloses are compositions containing specific dosages and/or ratios of long chain polyunsaturated fatty acids that are particularly effective in reducing or preventing symptoms of inflammation or neurodegeneration.
... |
| Dha esters and use thereof in treatment and prevention of cardiovascular disease | 20090312354 | 20091217 |
| The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.
... |
| Docosahexaenoic acid producing strains of yarrowia lipolytica | 20090311380 | 20091217 |
| An engineered strain of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 5.6% docosahexaenoic acid acid (DHA, an w-3 polyunsaturated fatty acid) in the total oil fraction is described. This strain comprises various chimeric genes expressing heterologous desaturases, elongases and acyltransferases and optionally comprises various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of DHA. Production host cells are claimed, as are methods for producing DHA within said host cells.
... |
| Compositions for alleviating inflammation and oxidative stress in a mammal | 20090311350 | 20091217 |
| An antioxidant-promoting composition that increases antioxidant defense potential in a subject is disclosed comprising Bacopa monniera extract; milk thistle extract, ashwagandha powder, green tea extract, Gotu kola powder, Ginko biloba leaf extract; Aloe vera powder; turmeric extract; and N-acetyl cysteine. The antioxidant-promoting composition of the invention safely induces cellular antioxidant potential to achieve an overall net decrease in oxidative stress without the undesirable side-effects associated with the individual components of the antioxidant-promoting composition. Also disclosed is a method for reducing the undesirable side-effects of free radicals in a subject by administering to a subject in need of such antioxidants an effective amount of antioxidant-promoting composition of the invention.
... |
| Deletion mutants for the production of isobutanol | 20090305369 | 20091210 |
| An E. coli host strain was engineered wherein genes adhE, IdhA, frdB, and pfIB were disrupted and novel butanol dehydrogenase gene, sadB, from Achromobacter xylosoxidans, was added to produce the isobutanol production host.
... |
| Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof | 20090305365 | 20091210 |
| The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturase family members. The invention also provides recombinant expression vectors containing desaturase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (LCPUFAs), e.g., DHA.
... |
| Oral composition comprising dha and genistein for enchancing skin properties | 20090286872 | 20091119 |
| Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the composition comprises genistein in an amount of from 0.0001% to 0.1% by 10 weight and the genistein and DHA exhibit an anti-ageing effect on skin.
... |
| Method of treating cancer by co-administration of anticancer agents | 20090263390 | 20091022 |
| The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin -2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents.
... |
| Compositions and methods for preventing or treating inflammatory bowel disease | 20090263855 | 20091022 |
| Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).
... |
| E. coli for efficient production of caratenoids | 20090253164 | 20091008 |
| An improved E. coli for carotenoid production comprising exogenous nucleic acids for expressing a carotenoid that the E. coli requires as necessary condition for the E. coli to reproduce. Some E. coli embodiments have diminished or abrogated expression of a gene in the group consisting of ldhA, frdA, poxB, pta, adhE, pykF, zwf, and maeB.
... |
| Delta-4 desaturase and its use in making polyunsaturated fatty acids | 20090253188 | 20091008 |
| Described here are Δ4 desaturases that convert all-cis-7,10,13,16,19-docosapentaenoic acid [“DPA”; 22:5 ω-3] to docosahexaenoic acid [“DHA”; 22:6 ω-3], with secondary activity in converting docosatetraenoic acid [“DTA”; 22:4 ω-6] to all-cis-4,7,10,13,16-docosapentaenoic acid [“DPAn-6”; 22:5 ω-6]. Also, described here are isolated nuclei acid fragments and recombinant constructs comprising such fragments encoding Δ4 desaturases as well as methods of making long chain polyunsaturated fatty acids [“PUFAs”] using this Δ4 desaturase in oleaginous yeast.
... |
| Process for the biological production of 1,3-propanediol with high titer | 20090253192 | 20091008 |
| The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a... |
| Compositions and methods for preventing or treating inflammatory bowel disease | 20090253791 | 20091008 |
| Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).
... |
| E. coli for efficient production of caratenoids | 20090253164 | 20091008 |
| An improved E. coli for carotenoid production comprising exogenous nucleic acids for expressing a carotenoid that the E. coli requires as necessary condition for the E. coli to reproduce. Some E. coli embodiments have diminished or abrogated expression of a gene in the group consisting of ldhA, frdA, poxB, pta, adhE, pykF, zwf, and maeB.
... |
| Delta-4 desaturase and its use in making polyunsaturated fatty acids | 20090253188 | 20091008 |
| Described here are Δ4 desaturases that convert all-cis-7,10,13,16,19-docosapentaenoic acid [“DPA”; 22:5 ω-3] to docosahexaenoic acid [“DHA”; 22:6 ω-3], with secondary activity in converting docosatetraenoic acid [“DTA”; 22:4 ω-6] to all-cis-4,7,10,13,16-docosapentaenoic acid [“DPAn-6”; 22:5 ω-6]. Also, described here are isolated nuclei acid fragments and recombinant constructs comprising such fragments encoding Δ4 desaturases as well as methods of making long chain polyunsaturated fatty acids [“PUFAs”] using this Δ4 desaturase in oleaginous yeast.
... |
| Process for the biological production of 1,3-propanediol with high titer | 20090253192 | 20091008 |
| The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a... |
| Compositions and methods for preventing or treating inflammatory bowel disease | 20090253791 | 20091008 |
| Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).
... |
| System of the chemical engineering processes generating energy and utilizing municipal solid waste or a carbon content material mixture | 20090241420 | 20091001 |
| A system of the interrelated chemical engineering processes that continuously and simultaneously gasify and utilize of an organic-inorganic raw material or municipal solid waste (MSW) and completely or entirely decompose and transform said raw material, synthesize synthetic gas (syngas) and water steam gas mixture, and melt inorganic materials that are made further treatment and correspondingly processed into following consumable and fully marketable materials or products: syngas fuel, electricity, methanol or gasoline, chemical materials, glassy slag and concrete/road filling materials, multi-metal alloy and cast metal goods, greenhouse made green mass, and hot water; said system of chemical engineering processes does not need or use fossil fuel and electric power supplied from external sources; and said system of processes excludes an emission of nitrogen oxide, carcinogenic, and hazardous... |
| Adaptogenic tea | 20090246300 | 20091001 |
| A natural adaptogenic tea is prepared from adaptogens to counter adverse physical, chemical, or biological stressors and to promote t-cell activity and k-cell activity. Also, the composition is high in antioxidants and discourages free radicals. Moreover, the composition improves liver performance, resulting in improved toxin removal and improved nutrient absorption. In addition to these benefits, the composition improves capillary dilation, thereby providing better oxygenation to the brain. The tea is prepared from adaptogens including rhodiola, ashwagandha, schizandra berry, eleuthero and astralagus. Also, the tea includes damiana leaf, passion flower, milk thistle, white willow bark, goji berry, mangosteen, pomegranate, green tea, and sarsaparilla.
... |
| Oral composition with an antiageing effect on the skin | 20090239945 | 20090924 |
| A composition which is adapted for oral consumption and which comprises: (i) a PPAR ligand; such as EPA or DHA (ii) an oestrogen receptor binding agent; such as soy isoflavones (iii) an agent that is involved in the post-translational modification of collagen; such as ascorbic acid and (iv) a carotenoid, wherein the composition is substantially free from added zinc and/or selenium, can provide an anti-ageing effect on skin and may be used to increase collagen synthesis in skin.
... |
| Reelin deficiency or dysfunction and methods related thereto | 20090215896 | 20090827 |
| A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or... |
| Method for treatment and prevention of respiratory insufficiency | 20090215897 | 20090827 |
| The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.
... |
| Reelin deficiency or dysfunction and methods related thereto | 20090215896 | 20090827 |
| A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or... |
| Method for treatment and prevention of respiratory insufficiency | 20090215897 | 20090827 |
| The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.
... |
| Reelin deficiency or dysfunction and methods related thereto | 20090215896 | 20090827 |
| A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or... |
| Method for treatment and prevention of respiratory insufficiency | 20090215897 | 20090827 |
| The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.
... |
| Reelin deficiency or dysfunction and methods related thereto | 20090215896 | 20090827 |
| A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or... |
| Method for treatment and prevention of respiratory insufficiency | 20090215897 | 20090827 |
| The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.
... |
| Reelin deficiency or dysfunction and methods related thereto | 20090215896 | 20090827 |
| A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or... |
| Method for treatment and prevention of respiratory insufficiency | 20090215897 | 20090827 |
| The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite induced respiratory insufficiency and/or dust mite allergy.
... |
| Composition for improving membrane composition and functioning cells | 20080317868 | 20081225 |
| the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... |
| Potato quality | 20080307844 | 20081218 |
| Potato quality is improved by applying to the plant or to the locus of the plant a composition comprising (a) a compound capable of forming a chelate with iron or (b) a chelate of iron with a chelate-forming compound. Specific quality improvements include increasing the dry matter content, increasing the starch content and reducing the reducing sugar content. A preferred iron chelate is that of EDDHA, available commercially as SEQUESTRENE 138 Fe 100.
... |
| Miniaturized wide-band baluns for rf applications | 20080303606 | 20081211 |
| A wide-band balun device includes a first metallization deposited over a substrate and oriented in a first coil. The first coil extends horizontally across the substrate while maintaining a substantially flat vertical profile. A second metallization is deposited over the substrate and oriented in a second coil. The second coil is magnetically coupled to the first coil and a portion of the second coil oriented interiorly of the first coil. A third metallization is deposited over the substrate and oriented in a third coil. The third coil is magnetically coupled to the first and second coils. A first portion of the third coil is oriented interiorly of the second coil. The third coil has a balanced port connected to the third coil between secondhand third portions... |
| Composition useful for the reduction of the cardiovascular risk and foods that contain it | 20080305214 | 20081211 |
| A composition is described suitable for addition to drinks and foods, the continued intake of which contributes to a decrease in the risk of cardiovascular disease, comprising the following active ingredients: beta glucans, at least one omega-3 fatty acid chosen among eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or triglycerides that contain it, vitamin E and folates; a bakery product and a drink are also described which are nutritionally balanced and which contain the aforementioned composition.
... |
| Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering omega-3 fatty acids | 20080306154 | 20081211 |
| Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression, and treating underlying risk factors for CVD such as hypertension, dyslipidemia, obesity and/or diabetes.
... |
| Substances for reducing occurence of major cardiac events in humans | 20080299187 | 20081204 |
| A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents.
... |
| Novel compounds | 20080300306 | 20081204 |
| A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.
... |
| Composition for improving membrane composition and functioning of cells | 20080292649 | 20081127 |
| c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... |
| Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage | 20080292681 | 20081127 |
| The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
... |
| Composition for improving membrane composition and functioning cells | 20080292724 | 20081127 |
| the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
... |
| Method for the fermentative production of l-amino acids with the aid of coryneform bacteria capable of using glycerin as the only carbon source | 20080293100 | 20081127 |
| The invention relates to a method for producing L-amino acids in which the following steps are carried out: a) the recombinant coryneform bacteria which produce the desired L-amino acid and in which at least one or several of the heterologous polynucleotides of the glycerol metabolism, selected among the group comprising glpA, glpB, glpC, glpD, glpE, glpF, glpG, glpK, glpQ, glpT, glpX, gldA, dhaK, dhaL, dhaM, dhaR, fsa, and talC, is/are expressed are cultivated in a medium containing glycerol or one or several other optional C sources in conditions in which the desired L-amino acid is enriched in the medium or the cells; and, optionally, b) the desired L-amino acid is isolated, all or fractions (>0 to 100 percent) of the components of the fermentation broth and/or... |
| B12 dependent dehydratases with improved reaction kinetics | 20080293119 | 20081127 |
| Sequences of B12-dependent dehydratases with improved reaction kinetics are presented. Use of these B12-dependent dehydratases reduce the rate of the enzyme's suicide inactivation in the presence of glycerol and 1,3-propanediol. The enzymes were created using error-prone PCR and oligonucleotide-directed mutagenesis to target the DhaB1 gene, which encodes the α-subunit of glycerol dehydratase. Mutants with improved reaction kinetics were rapidly identified using high throughput assays.
... |
| Nutritional food oil compositions and methods of making same | 20080280009 | 20081113 |
| Nutritional food oil compositions containing all of the essential fatty acids and the highly recommended omega-3 fatty acid DHA in correct proportions making it convenient and easy for consumers to supplement their diets with these fatty acids in the proper amounts, thereby deriving the health benefits of these fatty acids. A nutritional food oil composition is provided comprising alpha-linolenic acid (ALA) and linoleic acid (LA), wherein the ratio of the amount of ALA to LA in the composition by weight is in the range of 1.5:1 to 6:1, and together the ALA and LA comprise at least 65% by weight of the composition, and docahexaenoic acid (DHA) from an algal source in an amount greater than 0.5% by weight of the composition.
... |
| Method for diagnosing depression | 20080281531 | 20081113 |
| This invention relates to a method for diagnosing whether or not a subject suffers from depression in a simple manner with high accuracy using the peripheral whole blood sample of the subject. Specifically, the present invention relates to a method for diagnosing depression comprising the steps of: measuring expression levels of 18 genes selected from the group consisting of FASLG; CX3CR1, TBX21, ID2, SLAMF7, PRSS23, YWHAQ, TARDBP, ADRB2, PPP1R8, MMAA, SQLE, PDHA1, HAVCR2, RACGAP1, AHNAK, EDG8, and DUSP5, in peripheral blood isolated from a subject; and determining whether or not the subject suffers from depression based on the expression levels of the 18 genes.
... |
| Omega 3 fatty acid formulations | 20080268042 | 20081030 |
| The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.
... |
| Method of purifying oils containing epa and dha | 20080268117 | 20081030 |
| Oils are washed directly with a lower alcohol to remove cholesterol and other contaminants. The washing is effected at a temperature sufficiently low that the alcohol and oil remain immiscible. The composition is then heated to form a single phase. The solution is then cooled to below 10° C. to separate the alcohol and oil phases. Undesirable components, such as cholesterol, organic contaminants, and heavy metals remain in the alcohol phase, separate from the pure oil.
... |
| Grape sugar development | 20080269057 | 20081030 |
| Grape sugar development is improved by applying to the vine or to the locus of the vine a composition comprising an iron chelate. Advantages include increasing the overall sugar content of grapes and increasing the rate of development the sugar. A preferred iron chelate is the iron chelate of EDDHA, available commercially as SEQUESTRENE 138 Fe 100.
... |
| Effects of low n-6:n-3 fatty acid ratio from two dietary sources on plasma and tissue lipid composition | 20080269328 | 20081030 |
| Health benefits from low n-6:n-3 fatty acid (FA) ratio on cardiovascular risk have been shown. However, the impact of the source of n-3 FAs has not been fully investigated. Our purpose was to investigate cardiovascular benefits of oils with a low ratio of n-6:n-3 FAs, but different sources of n-3 FAs. Mice were divided into 3 groups (n=7) and fed a diet supplemented with either a fish or flaxseed oil-based ‘designer oils’ with an approximate n-6:n-3 FA ratio of 2/1 or with a safflower-oil-based diet with a ratio of 25/1, for 16 weeks. Plasma lipids and fatty acid profile of the liver and heart tissues were characterized. Plasma cholesterol levels were reduced in both fish and flax groups by 27% and 36%, respectively, as compared to... |
| Nutrition containing fat blend | 20080269330 | 20081030 |
| The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.
... |
| Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events | 20080269331 | 20081030 |
| The use of polyunsaturated fatty acids of the .omega.-3 series such as eicosapentaenoic acid (EPA, C.sub.20:5 .omega.-3), docosahexaenoic acid (DHA, C.sub.22:6 .omega.-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
... |
| Method for correcting a lipid imbalance in a subject | 20080269341 | 20081030 |
| The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance, comprising (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, (c) increasing DHA/AA ratio or (d) any combination of (a)-(c) in a subject using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.
... |
| Enzymatic method for producing dihydroxyacetone phosphate | 20080248532 | 20081009 |
| c) dephosphorylating the phosphate of step b) by treating the phosphate with a bacterial acid phosphatase.
... |
| Method of detoxication of yperite by using haloalkane dehalogenases | 20080248557 | 20081009 |
| The method of detoxification of yperite—bis(2-chloroethyl)sulfide—by the use of a haloalkane dehalogenases or their compositions, the method of preparation of dehalogenationating enzymes and of decontamination compositions which contains at least one wild type and/or modified haloalkane dehalogenase (EC 3.8.1.5) as an chemically active component. The preferred dehalogenases are LinB from Sphingomonas paucimobilis UT26, DhaA from Rhodococcus rodochrous NCIMB 13064, DmbA from Mycobacterium bovis 5033/66. Decontamination is utilizable for detoxification of yperite from the surfaces of instrumentality, constructional objects, human or animal skin and elements of environment by the treatment of yperite with the detoxification composition according the invention at +10° C. to +70° C., preferably at about +40° C. and pH from 4 to 12.
... |
| Scroll fluid machine | 20080240956 | 20081002 |
| a plurality of second plate sprigs 112c and 112d that connects the intermediate ring and the stationary scroll 58, while supporting the intermediate ring 110 so as to enable the intermediate ring 110 to move in a second direction orthogonal to the rotation axis (of the machine) as well as orthogonal to the first direction.
... |
| Scroll fluid machine | 20080240957 | 20081002 |
| The object is to provide a scroll fluid machine in which relative revolving motion is produced between two scrolls engaging with each other without using conventional Oldham coupling or pin crank type mechanism which has sliding parts. The scroll compressor 50 comprises a stationary scroll 58 fixed to a scroll casing 60, a revolving scroll 52, a rotation shaft 86 having an offset portion 100 for revolving the revolving scroll 52, and plate springs 110a 110b that connect the stationary scroll to the revolving scroll in a state surrounding the scroll laps of the scrolls.
... |
| Self-tanning composition, use of dha in combination with mineral oil, and a skin self-tanning method | 20080213201 | 20080904 |
| The present invention relates to a cosmetic and/or dermatological self-tanning composition containing reduced DHA content and that uses the unexpected synergistic tanning effect of the joint use of DHA and mineral oil in obtaining an even tan, without stains and without producing skin dryness. The composition exhibits an improved stability by virtue of the lower DHA concentration and, through combination of specific components present in its composition, provides skin hydration together with self-tanning.
... |
| Methods and organisms for growth-coupled production of 3-hydroxypropionic acid | 20080199926 | 20080821 |
| The invention provides a non-naturally occurring microorganism having one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory coupling 3-hydroxypropionic acid production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby the one or more gene disruptions confers stable growth-coupled production of 3-hydroxypropionic acid onto the non-naturally occurring microorganism. Also provided is a non-naturally occurring microorganism comprising a set of metabolic modifications obligatory coupling 3-hydroxypropionic acid production to growth of the microorganism, the set of metabolic modifications having disruption of one or more genes including: (a) the set of genes selected from: (1) adhE, ldhA, pta-ackA; (2) adhE, ldhA, frdABCD; (3) adhE, ldhA, frdABCD, ptsG; (4) adhE, ldhA, frdABCD, pntAB; (5)... |
| Highly purified ethyl epa and other epa derivatives | 20080200547 | 20080821 |
| A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
... |
| Nutritionally enhanced nut product | 20080193605 | 20080814 |
| Methods and compositions are described to prepare an enhanced nut butter product by replacing a portion of nut oil in the formulation of an unenhanced butter with one or more oils, such that the enhanced nut butter product has, when compared to the unenhanced nut butter: a higher level of monounsaturated fatty acids reported to have health benefits; a higher level of long chain omega-3 fatty acids (EPA/DHA) reported to have health benefits; a lower overall fat content; similar or improved texture and taste; the ability to have FDA health claims on its label as a result of the added oils; and having oils in its formulation that are preferred by consumers. Embodiments include peanut butter and almond butter.
... |
| Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard) | 20080181937 | 20080731 |
| Methods and compositions for preventing memory loss and reducing the onset of Alzheimer's disease and the pathological symptoms associated therewith including memory loss, reduced cognitive function and dementia are provided. These methods and compositions comprise dosage regimens that provide for the daily administration of effective amounts of Vitamin C, Vitamin E, DHA, and Curcumin.
... |
| Food fortified with omega-3 fatty acids | 20070298079 | 20071227 |
| A food product is provided which is fortified with omega-3 fatty acids. The omega-3 fatty acids include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The omega-3 fatty acids are added to the food product in a desired amount and blended sufficiently by mixing.
... |
| Power tool | 20070289762 | 20071220 |
| An elastic unit includes a transatory unit including a first elastic support member, a second elastic support member and not-shown four round bar-shaped elastic bodies made of rubber. A rotation urging unit is composed of a Neidhart spring including an outer frame, a shaft, a rotary member, and four rubber rods. The rotary member is in a state where it is rotated at 10° counterclockwise from an initial state. Therefore, the rubber rod deforms upon reception of rolling friction from the outer frame and the rotary member, and the rotation urging unit gives the handle portion the urging power by which the handle portion is rotated so that one end of the handle portion is spaced away from a gear housing 31 in the direction of... |
| Dairy product | 20070280998 | 20071206 |
| The present invention provides a novel feedstock and method of feeding dairy cows. Milk products derived from cows fed the feedstock are also encompassed. Milk comprising at least 0.3% DHA/g of fatty acids and food products containing components of that milk are also included. The milk product of the invention also contains elevated levels of DPA and EPA.
... |
| Nucleic acid-binding chips for the detection of phosphate deficiency conditions in the framework of bioprocess monitoring | 20070281312 | 20071206 |
| The present application relates to nucleic acid-binding chips for monitoring bioprocesses, especially for detecting phosphate deficiency conditions. Said chips support probes for at least three of the following 47 genes: yhcR, tatCD, ctaC, gene for a putative acetoin reductase, spoIIGa, nasE, pstA, spoIIAA, gene for a hypothetical protein, yhbD, cotE, gene for a conserved hypothetical protein, yurl, spoVID, gene for a putative aromatic-specific dioxygenase, yhbE, gene for a putative benzoate transport protein, pstBB, spoIIIAH, gene for a hypothetical protein, spoIIQ, spoIIIAG, yvmA, gene for a putative ribonuclease, dhaS, yrbE, gene for a putative decarboxylase/dehydratase, htpG, yfkH, spoIIAB, spoIIIAF, alsD, gdh, yfkN, pstC, yfmQ, pstBA, dhaS homolog, gene for a putative phosphatase, phy, cypX, alsS, phoD, pstS, phoB, yvnA, yvmC, the total number of phosphate metabolism-specific different... |
| Trainline support bracket | 20070267377 | 20071122 |
| A trainline support bracket for connection to a railcar having a yoke and a coupler attached to the railcar and a coupler-uncoupling mechanism housing attached to the coupler having first and second side walls with first and second contoured recess members thereon, and having upper and lower compartments for attaching the trainline support bracket thereto. The trainline support bracket includes a main body connector having an upper connector section and a lower connector section. The upper connector section of the main body connector is for connecting to the coupler-uncoupling mechanism housing of the coupler. The trainline support bracket also includes a lower connecting bracket having a first end and a second end. The lower connector section of the main body connector is for detachably connecting to... |
| Liquid egg product | 20070269561 | 20071122 |
| A novel food composition is provided in which omega-3 fatty acids, preferably including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), particularly in the form of fish oil, is provided in a liquid egg product.
... |
| Roll rotation mechanism | 20070265102 | 20071115 |
| In a roll rotation mechanism (1) for continuously causing a film-rolling roll to rotate at a constant rate, an Oldham coupling (4) is interposed in a transmission path between a wave gear reduction mechanism (3) and a roll (10). The Oldham coupling (4) forms a connection between a gear rotation output shaft (34) and a roll rotation shaft (11) in a state in which latitude of movement α is present about a central axis line (4a). When a roll (10) is continuously rotated at a constant rate, the Oldham coupling (4) is held in a state in which no latitude of movement is present in a rotation direction R and latitude of movement α is present in a direction opposite the rotation direction; and rotation torque... |
| Method and device for measuring the texture of cooked grains | 20070259078 | 20071108 |
| A method and device for assessing end point of cooking of dhal and rice with good reproducibility are disclosed. Pulses are generally consumed as dhals after cooking to soft texture. Measurement of end point of cooking of dhals, rice etc is very subjective and current methods are not very satisfactory. An innovative device and an objective method for carrying out the same were developed. This works on the principle of determining the “spread area” during progressive cooking for dhals as well as rice, and reading the cooking time form a graph plotted. The device developed for the purpose can be used to exert the desired force for pressing the cooked grain and the area to which the grain spreads is determined by counting the number of... |
| Antimicrobial compounds | 20070259406 | 20071108 |
| The present invention relates to new antimicrobial compounds, in particular proteins, having the amino acid sequence XAlaUValLeuLysOUIleLysValAlaLysLysTyrAlaLysGlyValA*LeuA*AlaGlyAlaAsnIleOGlyGlyLys wherein X is hydroxy propionyl (Hop), U is α,β-didehydroalanine (Dha), O is α,β-didehydrobutyrine (Dhb), A* is aminobutyrine (Abu), wherein lanthionine ring structures are formed between Ala12 and Ala16, between Abu20 and Ala23 and between Abu22 and Ala25, and in which at least one amino acid has been replaced by another amino acid.
... |
| Liquid egg product | 20070224334 | 20070927 |
| A novel food composition is provided in which omega-3 fatty acids, preferably including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), particularly in the form of fish oil, is provided in a liquid egg product.
... |
| Nutritional compositions and methods | 20070225370 | 20070927 |
| The invention is an anti-inflammatory composition comprising a mixture comprising two components, a first component rich in EPA and a second component rich in GLA. The first component is a mixture comprising EPA and preferably DHA comprising at least 35% EPA, preferably 50% EPA and more preferably 60% or more of EPA, and up to 25% DHA, preferably up to 10% DHA, possibly 0% DHA. The second component comprises at least 20% GLA, preferably 60%, and more preferably 70% GLA. The preferred composition comprises between about 60 and 80% of the first component and 20% and 40% of the second component.
... |
| Topical treatment with ngf and dha in damaged corneas | 20070218105 | 20070920 |
| The topical administration of a combination of nerve growth factor (NGF) and docosahexaenoic acid (DHA) has been discovered to synergistically increase the effects of NGF in re-innervating the cornea. This enhancement in corneal nerve re-growth will yield a faster anatomical and functional recovery after PRK or LASIK surgeries. Using rabbits, the application of NGF and DHA resulted in increased corneal nerve surface area, increased epithelial proliferation, and decreased rose bengal staining as compared with NGF, DHA, or vehicle control individually. The topical application of NGF plus DHA in accelerating the re-innervation after PRK or LASIK, will help avoid or alleviate the symptoms of dry eye or other neurotrophic keratopathies due to corneal injuries. The topical application can be by using a corneal shield or lens. This... |
| Health bars and compositions for improving cardiovascular risk factors | 20070218113 | 20070920 |
| The invention provides, in one aspect, a method of administering a product comprising beta glucan, soy protein, phytosterols, and an omega-3 fatty acid, such as one or more of DHA and EPA, to improve cardiovascular risk factors, such as LDL levels or total cholesterol levels. The amount of each of beta glucan, soy protein, phytosterols, and omega-3 fatty acids is selected from the amount providing the beneficial health effects associated with the health claims for these compositions or ingredients. Methods of making nutritional health bars and food ingredients that comprise the same compositions and ingredients in effective amounts that are shelf-stable are also disclosed.
... |
| Pharmaceutical compositions containing pufa and at least one of an immunosuppressive agent or an antineoplastic agent | 20070219271 | 20070920 |
| Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacologically acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Chrohn's disease and ulcerative colitis) and tumour disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased.
... |
| Drain valve | 20070209705 | 20070913 |
| A drain valve for a vehicle compressed air system. The drain valve including a body portion is adapted to separate water, debris and other relatively heavy objects from a compressed air stream passing through the valve and a gladhand portion capable of connecting to a gladhand connector. The drain may also include a pressure actuated valve and drain port for automatically discharging water from the drain valve.
... |
| Vehicular disk brake | 20070209888 | 20070913 |
| A speed reducer 32 has an eccentric rotating member 56 which rotates along with a motor shaft 55 of an electric motor 11, an outer gear 57 which is rotatably supported by the outer circumference of the eccentric rotating member 56, an inner gear 58 which is fixedly disposed so as to be coaxial with the motor shaft 55 so as to engage with the outer gear 57, an output member 59 which is connected to an input member 37 of the motion converting mechanism 22 disposed so as to be coaxial with the motor shaft 55 so as to be not relatively rotatable about the input member 37, and an Oldham mechanism 60 which is disposed between the outer gear 57 and the output member... |
| Motor-compressor unit mounting arrangement for compressors | 20070201996 | 20070830 |
| A method of assembling a compressor, including assembling, first as a subassembly external of the compressor housing, portions of the motor-compressor unit, including a crankcase, mount brackets, stator, outboard bearing assembly, and drive shaft. Thereafter, the motor-compressor unit subassembly is inserted into a first end of the housing, and the housing is shrink-fit around the subassembly. The mount brackets may then be welded to the interior surface of the housing. Once the mount brackets are welded to the housing, the remainder of the components of the motor-compressor unit, including the orbiting scroll member, the Oldham coupling, and the fixed scroll member, are then assembled to the motor-compressor unit subassembly and the housing through a second end of the housing opposite the first end, followed by welding... |
| Method for increasing the expression of pulmonary surfactant protein-b | 20070202052 | 20070830 |
| The present invention is directed to a novel method for increasing the expression of pulmonary surfactant protein-B in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the infant.
... |
| Method for preventing or treating anemia | 20070203235 | 20070830 |
| The present invention is directed to a novel method for preventing or treating anemia in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA to the subject.
... |
| Method for preventing or treating obesity | 20070203237 | 20070830 |
| The present invention is directed to a novel method for preventing or treating obesity in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.
... |
| Method for preventing or reducing elevated triglyceride levels | 20070203238 | 20070830 |
| The present invention is directed to a novel method for reducing triglyceride levels in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.
... |
| Pufa supplements | 20070184090 | 20070809 |
| Edible formulations, such as polyunsaturated fatty acids (PUFAs) such as pharmaceutical compositions or nutritional supplements, are disclosed comprising arachidonic acid (ARA). They are adapted to deliver from 150 mg to 1 g per day of ARA and may contain other PUFAs, for example docosahexaenoic acid (DHA). The DHA dosage is from 400 to 600 mg per day, and the ratio of ARA:DHA may be from 1:5 to 5:1. Pharmaceutical compositions comprising ARA and DHA at a ratio of ARA:DHA of 1:1 to 1:2 are also disclosed, as are foodstuffs comprising 0.1 to 5% ARA. Such formulations can be used to increase ARA levels in vivo, for example in pregnant women or for people who have diseases or conditions associated with low ARA levels.
... |
| Compositions and methods for preventing or treating inflammatory bowel disease | 20070185201 | 20070809 |
| Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).
... |
| L-glutamic acid-producing microorganism and a method for producing l-glutamic acid | 20070172932 | 20070726 |
| A coryneform bacterium which has an L-glutamic acid-producing ability and grows at least at the same growth rate as a non-mutated strain or a wild-type strain and has intracellular α-ketoglutarate dehydrogenase activity which is less than half that of the non-mutated or wild-type strain, and is obtained by introducing a mutation into a coding region or an expression control region of the chromosomal odhA gene encoding the E1o subunit of the α-ketoglutarate dehydrogenase complex.
... |
| Yoga belt and method of use | 20070173382 | 20070726 |
| A yoga belt to assist in Dhanurasana (Bow Pose) prevents lumbar and sacroiliac problems arising from the exercise or asana. The belt includes a first portion, a second portion, a third portion, a first loop positioned between the first portion and the second portion, and a second loop positioned between the second portion and the third portion. The user picks up the belt and places one loop over one foot and the other loop over the other foot. Each belt strap should be pulled through the inside part of the foot to maintain the integrity of the thighs and feet in an effort to remain hip width apart. The user then faces forward with the elbows under each shoulder and is ready to begin.
... |
| Nutritional supplement containing long-chain polyunsaturated fatty acids | 20070166411 | 20070719 |
| The present invention relates to a nutritional supplement for administration to children. The supplement comprises a protein component, a carbohydrate component, and a fat or lipid component which further comprises a source of DHA. The supplement has an ω-6:ω3 fatty acid ratio of about 6:1 or less. The present invention also relates to a method of providing nutrition to a pediatric subject comprising administering to the subject a nutritional supplement comprising a protein component; a carbohydrate component; and a fat or lipid component, which further comprises a source of DHA, wherein the composition has an ω-6:ω-3 fatty acid ratio of about 6:1 or less.
... |
| Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances | 20070161705 | 20070712 |
| The use is described of a composition comprising either a) alpha-linolenic acid (ALA, C18:3 n-3) or b) docosahexaenoic acid (DHA, C22:6 n-3) or c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof; either a) or b) or c) being in a concentration not lower than 70% by weight of the total fatty acids weight in the composition, for the preparation of a drug for the prevention and/or treatment of the disturbances of the central nervous system (CNS) such as epilepsy, schizophrenia, bipolar (manic-depressive illness) and unipolar (major depression) psychiatric disorders, and by degenerative Alzheimer's disease and related forms of dementia.
... |
| Genes involved in polyketide synthase pathways and uses thereof | 20070148747 | 20070628 |
| The subject invention relates to isolated nucleic acid sequences or genes involved in polyketide synthase (PKS) biosynthetic pathways. In particular, such pathways are involved in the production of polyunsaturated fatty acids (PUFAs) such as, for example, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). Specifically, the invention relates to isolating nucleic acid sequences encoding proteins involved in eukaryotic PUFA-PKS systems and to uses of these genes and encoded proteins in PUFA-PKS systems, in heterologous hosts, for the production of PUFAs such as EPA and DHA.
... |
| Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs | 20070149617 | 20070628 |
| The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 triglyceride and/or diglycerides comprise at least 40% EPA and/or DHA. The present invention also provides novel fish-oil compositions for administration after an ischemic insult to limit cell death in the organ that underwent an ischemic event.
... |
| Omega 3 fatty acid formulations | 20070141138 | 20070621 |
| The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.
... |
| Use of resolvins to treat gastrointestinal diseases | 20060293288 | 20061228 |
| The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA and DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate gastrointestinal conditions, for example, such as colitis. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for... |
| Baby-food compositions enhancing visual acuity and methods therefor | 20060286267 | 20061221 |
| Baby-food compositions that enhance visual acuity upon feeding to an infant are disclosed. The compositions contain docosahexaenoic acid (DHA) in an amount of at least about 0.5 mg per gram of the composition. The source of the DHA can be from DHA-enriched coagulated egg yolk solids present in an amount of from about 5% to about 25% (grams/100 grams). The compositions have an organoleptically acceptable smooth texture as a result of contain an acidulant or as a result of being processed by a microcutter. Also disclosed are methods for enhancing visual acuity in infants and methods of providing the compositions to a consumer.
... |
| Interpolymers suitable for use in hot melt adhasives and processes to prepare same | 20060287444 | 20061221 |
| The present invention relates to an ethylene/α-olefin interpolymer product comprising at least one α-olefin interpolymerized with ethylene and, characterized in at least one aspect, as having improved properties when utilized in a hot melt adhesive formulation. The invention also relates to a process for manufacturing the interpolymer product wherein the process comprises employing two or more single site catalyst systems in at least one reaction environment (or reactor) and wherein the at least two catalyst systems have (a) different comonomer incorporation capabilities or reactivities and/or (b) different termination kinetics, both when measured under the same polymerization conditions. The interpolymer products are useful, for example, in applications such as hot melt adhesives, and also for impact, bitumen and asphalt modification, adhesives, dispersions or latexes and fabricated articles... |
| Recognition award, personnel identification holder and/or personnel unit for attachment to hardhats, protective helmets or the likes | 20060272189 | 20061207 |
| A device for displaying a recognition award includes a hard hat having a pocket, a detachable connected holder to be placed in the pocket and a personnel unit adapted to display the recognition award and adapted to be positioned in the detachedly connected holder. The device is used as a recognition award or personnel identification unit to be retained within a detachedly connected holder.
... |
| Synergistic effects of docosahexaenoic acid (dha) and carotenoid absorption on macular pigmentation | 20060270739 | 20061130 |
| The present invention provides compositions and methods for increasing the absorption of dietary carotenoids in humans. The methods and compositions of the invention can used to increase the concentration of retinal lutein and zeaxanthin, thereby preventing the onset and/or slowing the progression of macular degeneration. Pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of a lutein and docosahexaenoic acid (DHA) are disclosed.
... |
| Dynamic hierarchical address resource management architecture, method and apparatus | 20060256736 | 20061116 |
| A Dynamic Hierarchical Address Resource Management Architecture (DHARMA) coordinates a logical hierarchy of address spaces with a virtual topology of network elements using a manageable database environment. Address spaces are apportioned into hierarchical levels in accordance with a network policy. Network elements may be represented as objects, coupled via the logical address space. Both address space hierarchy definition and virtual topology modelling may occur independent from actual network deployment. As a result, multiple address space hierarchy definitions and virtual topologies can be pre-generated and stored for selective use during network deployment. With such an arrangement, a flexible addressing architecture is provided which may advantageously be: used in any network that desires dynamic network configuration. The connection between the logical address hierarchy and the virtual network topology... |
| Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders | 20060252833 | 20061109 |
| A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
... |
| Nutritional supplements for cardiovascular health | 20060228403 | 20061012 |
| An admixture containing as active ingredients omega-3 polyunsaturated fatty acids selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linoleic acid (LNA), curcumin, B complex vitamins selected from folic acid, B6 and B12, antioxidant vitamins selected as vitamin C and vitamin E and ubiquinone. This compound is being designed for the support of cardiovascular health.
... |
| Method for preventing or treating respiratory infections in infants | 20060229366 | 20061012 |
| The present invention is directed to a novel method for preventing or treating respiratory infections in infants. The method comprises administration of a therapeutically effective amount of DHA and ARA to the infant.
... |
| Nutritional preparations | 20060217385 | 20060928 |
| Compositions and methods for improving the nutritional and physiological status of a woman and her child during all stages of pregnancy are provided herein. This includes pre-conceptional women, pregnant women, and post-natal women (both lactating and non-lactating mothers). The compositions are particularly useful for the neurological, visual, and cognitive development of an embryo, fetus, or infant and the nutritional and physiological well-being of the mother, fetus, and infant. The compositions contain one or more folates, such as a reduced folate and/or folic acid, and one or more essential fatty acids (EFA), such as an omega-3 and/or omega-6 fatty acid. The addition of the essential fatty acid improves upon the folate containing nutritional preparations described in the prior art. The one or more folates and essential fatty... |
| Nutritional preparations | 20060217386 | 20060928 |
| Compositions and methods for improving the nutritional and physiological status of a woman and her child during all stages of pregnancy are provided herein. This includes pre-conceptional women, pregnant women, and post-natal women (both lactating and non-lactating mothers). The compositions are particularly useful for the neurological, visual, and cognitive development of an embryo, fetus, or infant and the nutritional and physiological well-being of the mother, fetus, and infant. The compositions contain one or more folates, such as a reduced folate and/or folic acid, and one or more essential fatty acids (EFA), such as an omega-3 and/or omega-6 fatty acid. The addition of the essential fatty acid improves upon the folate containing nutritional preparations described in the prior art. The one or more folates and essential fatty... |
| Methods for the diagnosis, prognosis and treatment of metabolic syndrome | 20060211020 | 20060921 |
| The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2.
... |
| Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | 20060205814 | 20060914 |
| The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.
... |
| Method and apparatus for converting a routing table into a collection of disjoint zones | 20060200580 | 20060907 |
| The present invention discloses a method for analyzing an IP Gateway's Routing Table for identifying sets of IP addresses (“Disjoint Zones”) communicating through the same Gateway, said method comprising the steps of: identify subnets of IP addresses which are directly connected to the Gateway(“directly-connected subnets”) via a network interface card (“NIC”); associate every route in the Routing Table with a NIC; identify and sort the Routing Table's Critical Points, at which the routing decision may change between successive IP addresses, and identifying Disjoint Zones of IP addresses by locating all the Critical Points at which the routing decision in fact changes between successive IP addresses. According to a further option of the present invention, an External Disjoint Zone is identified in accordance with the NIC which... |
| Apparatus and method of treating fine powders | 20060193978 | 20060831 |
| The present invention relates to an apparatus and method for economic treatment of Geldhart class C or larger substrate powders of single or plural metal, ceramic, or polymeric materials. In particular, the present invention is directed to coating such powder via a fluidized CVD or PVD, electroless, electrochemical, or solution chemistry plating process, and provides processes and apparatus for accomplishing same. It is particularly suited to coating with single or plural layers of metal, ceramic, binder, sintering aid, or polymer onto such materials without agglomeration. The coated particles and products made therefrom exhibit novel physical properties that are not limited by classical chemical and thermodynamic constraints.
... |
| Gladhand grip | 20060186661 | 20060824 |
| A gladhand grip device (10) is adapted to be attached to one portion (11) of a gladhand coupling and to surround a marginal end portion of a hose (H) connected to the coupling portion to allow an operator to more easily apply a torque to the coupling portion when connecting or disconnecting the coupling and to protect the hose marginal end portion against acute flexure. The device includes: an adapter (12) having a first threaded portion (20) adapted to matingly engage the coupling portion; and a handle assembly (13) surrounding the hose marginal end portion and having a first end and a second end, a marginal portion of the handle assembly about the first end being adapted to be selectively attached to the adapter, the handle... |
| Gene targets for enhanced carotenoid production | 20060188955 | 20060824 |
| The present invention provides genetically manipulated cells and methods for utilizing same. Methods of enhanced carotenoid synthesis utilizing cells genetically disrupted for a yjiD, hnr or yjfP gene, or further disrupted for a gdhA, gpmB aceE, ppc, talB or fdhF gene, or any combination thereof, or cells inhibited for their expression, activity or function are disclosed. Methods of enhanced carotenoid synthesis utilizing cells genetically engineered to overexpress dxs, idi, yjiD, rpoS, torC, appY, ydgK, yeiA, yedR, tort, arcB, yggT, purDH, yfjN or a combination thereof, or further disrupted for the above-referenced genes are disclosed. Methods for identifying genes involved in optimized production of a carotenoid, and cells disrupted for, or inhibited for the expression, activity or function of genes thus identified are described.
... |
| Process for the preparation of cephradine | 20060189802 | 20060824 |
| The present invention describes a process for preparing cephradine, said process comprising reacting 7-aminodesacetoxy cephalosporanic acid (7-ADCA) with D-dihydrophenylglycine in activated form (DHa) in the presence of an enzyme in a reaction mixture to form cephradine, resulting in a conversion of 7-ADCA into cephradine of at least 70%, wherein the concentration D-dihydrophenylglycine (DH) in the reaction mixture is below 2 wt.%, wherein the conversion of 7-ADCA into cephradine & equals; (nCEF/n7-ADCA)*100%, wherein nCEF=quantity of cephradine formed (in mole); and n7-ADCA=total quantity of 7-ADCA added to reaction mixture (in mole). The invention also describes a process for the preparation of cephradine hydrate characterised in that the process comprises: —reacting 7-amino acid desacetoxy cephalosporanic acid (7-ADCA) with DHa in the presence of an enzyme in a reaction mixture... |
| Sunless tanning products and processes | 20060177398 | 20060810 |
| Sunless tanning compositions are substantially improved by adding methylsulfonyl methane [MSM] and certain glycols to Dihydroxyacetone (DHA).
... |
| Enzymatically synthesized marine phospholipids | 20060177486 | 20060810 |
| This invention discloses an improved enzymatic process, under organic solvent free conditions, for the incorporation of fatty acids such as omega-3 fatty acids into phospholipids. The rate of transesterification is increased 4 times by adding a base to the reaction mixture, typically an amine. The invention also discloses novel phospholipid compositions as well as novel use of the phospholipid compositions as a food supplement, a fish feed, animal feed and human food. In addition to methods for enriching prey organisms used in aquaculture, methods of reducing arachidonic acid levels in mammalian plasma/red blood cells and methods for increasing DHA levels in the mammalian brain.
... |
| Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction | 20060166935 | 20060727 |
| This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's disease, as well as treatment/prevention of cognitive dysfunction.
... |
| Polynucleotides of dha and isoforms of eif-5a and methods of using same | 20060162022 | 20060720 |
| The present invention relates to unique isoforms of eukaryotic initiation Factor 5A (“eIF-5A”): senescence-induced eIF-5A; wounding/pathogen induced eIF-5A; stress eIF-5A and growth eIF-5A, as well as polynucleotides that encode these three factors. The present invention also relates to methods involving modulating the expression of these factors. The present invention also relates to deoxyhypusine synthase (“DHS”), polynucleotides that encode DHS, and methods involving modulating the expression of DHS.
... |
| Steering device | 20060151235 | 20060713 |
| A variable steering gear mechanism (9) is constructed of an external gear (15) connected to an input shaft (11), an internal gear (16) fixed to housing (10) and meshing with the external gear (15), an intermediate member (19) receiving a rotary force transmitted from the external gear (15), change means (18a, 31, 33a) capable of changing a rotation ratio of the output shaft (33) to a rotation of a guide member (18), and an Oldham coupling (17) connecting the intermediate member (19) to the guide member (18). When a speed reduction ratio thereof is set to, e.g., 6:1, it follows that the input member (18) of the change means makes a ¼ rotation (rotates through 90 degrees) during one-sided 1.5 rotations (540 degrees) of the input... |
| Lipase-catalysed esterification of marine oil | 20060148047 | 20060706 |
| Marine oil compositions which contain EPA and DHA as free acids or hexyl esters are esterified with ethanol in the presence of a lipase catalyst under essentially organic solvent-free conditions and separated by distillation.
... |
| Process for the biological production of 1,3-propanediol with high titer | 20060148053 | 20060706 |
| The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a... |
| Electric oil pump | 20060140805 | 20060629 |
| An object of the invention is to provide an electric oil pump with greatly improved operation, increased endurance, and extended service life of an Oldham's coupling connecting a drive shaft that rotates a rotor in a pump housing and a motor output shaft in a motor housing. The electric pump comprises a pump housing having a rotor and a drive shaft for rotatably supporting the rotor, and a motor housing connected to the pump housing and having an output shaft connected to the drive shaft via an Oldham's coupling. The pump housing is provided with a coupling chamber for accommodating the Oldham's coupling, and a linking channel for transporting the leaked oil from a rotor chamber accommodating the rotor of the pump housing to the coupling... |
| Herbal nutritious chocolate formulation and process for preparation thereof | 20060141066 | 20060629 |
| The present invention provides a novel herbal chocolate composed of Tinospora cordifolia, Glycyrrhyza glabra, Adhatoda vasica, Madhuca indica and Cassia occidentalis. The solid or semisolid nutritious composition is rich in protein/mineral fortified with standardized herbs with proven pharmacological activities such as anti-oxidant, anti stress and adaptogenic property and relief the chronic cough and cold.
... |
| Simultaneous anaerobic production of isoamyl acetate and succinic acid | 20060141594 | 20060629 |
| In vivo method of producing esters from acetyle coA, such as isoamyl acetate and succinate, has been developed by producing null mutants in pathways that use acetyl coA and by overexpressing products that use NADH and in order to maintain the proper redox balance between NADH and NAD+. The method is exemplified with null mutations in ldhA, adhE, ackA-pta and overexpression of pyruvate carboxylase and alcohol acetyltransferase. This strain produces higher levels of both isoamyl acetate and succinate.
... |
| Ppargamma-activating pharmaceutical composition | 20060142391 | 20060629 |
| The present invention relates to PPARγ-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPARγ-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPARγ-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.
... |
| Product and method for oral administration of nutraceuticals | 20060134294 | 20060622 |
| A delivery system for nutraceuticals uses a low caloric chocolate base for containing one or more nutraceuticals, either blended with the chocolate itself, or added as a liquid or crème filling. The chocolate has a relatively high level of oligomeric proanthocyanadins, and preferably further includes a phytosterol and DHA, as well as being sweetened with a sweetener blend containing tagatose and a secondary low caloric, high intensity sweetener, preferably Lo Han Guo extract. Using the inventive system, delivery of nutraceuticals in unit dosage form is facilitated, as the selected dose is carried within individual chocolate product pieces that taste substantially the same as conventional chocolate, though with few calories from carbohydrates, or effects on insulin response encountered with typical chocolate formulations.
... |
